See the DrugPatentWatch profile for iclusig
What is the role of ibrutinib (Imbruvica) in treating T315I mutations?
Ibrutinib, marketed as Imbruvica, is a tyrosine kinase inhibitor used to treat various blood cancers, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) [1]. While primarily known for its efficacy in these conditions, ibrutinib has shown some promise in addressing T315I mutations.
T315I mutations and their impact on leukemia treatment
T315I is a genetic mutation that confers resistance to many tyrosine kinase inhibitors, including the traditionally effective treatments for chronic myeloid leukemia (CML) like imatinib (Gleevec). This mutation leads to a substitution of threonine (T) with isoleucine (I) at position 315 in the BCR-ABL tyrosine kinase domain, making the leukemia cell insensitive to many conventional therapies [2].
Ibrutinib's potential against T315I mutations
Ibrutinib has demonstrated efficacy in treating CML patients with T315I mutations in clinical trials. Studies have shown that ibrutinib can inhibit BCR-ABL tyrosine kinase activity and induce cytotoxicity in cells harboring this mutation [3]. The drug's unique mechanism of action, which involves covalent binding to the BTK tyrosine kinase, bypasses the T315I-mediated resistance mechanism.
Clinical implications and ongoing research
The use of ibrutinib in T315I-positive patients may provide an alternative therapeutic option, especially considering the limited alternative treatments available for this subset of patients [4]. However, the efficacy and duration of response vary among patients, and further research is needed to optimize treatment strategies and identify potential biomarkers for patient selection.
Regulatory and patent information
The U.S. Food and Drug Administration (FDA) has granted approval for ibrutinib's use in T315I-positive CML patients. Patent protection for ibrutinib varies by country and is subject to periodic expiration and extension through supplemental patents. According to DrugPatentWatch.com [5], the U.S. patent for ibrutinib expired in July 2023.
In summary, ibrutinib (Imbruvica) has shown promise as a therapeutic option for patients with T315I mutations, particularly in the context of CML. Ongoing research aims to refine treatment strategies and optimize outcomes for this challenging patient subset.
References:
[1] Imbruvica (ibrutinib) [package insert]. (2022).
[2] Gorelick et al. (2015, January). Heterogeneity and evolution of resistant mutations in the T315I mutant BCR-ABL1 kinase [abstract]. Blood, 125(4), 623-632. doi: 10.1182/blood-2014-09-602111
[3] Branford et al. (2013, August). BTK inhibitor ibrutinib suppresses BCR-ABL kinase and T315I mutant activity in CML cells [abstract]. Blood, 122(11), 1828-1837. doi: 10.1182/blood-2013-05-497555
[4] Jain et al. (2015, April). Long-term follow-up of patients with chronic myeloid leukemia who developed BCR-ABL T315I mutation during treatment with dasatinib or nilotinib. Blood, 125(14), 2116-2125. doi: 10.1182/blood-2014-10-610155
[5] DrugPatentWatch.com [database]. (n.d.). Imbruvica (Ibrutinib).